SCYNEXIS Inc SCYX

Healthcare

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

NDAQ:SCYX - Post by User

SCYNEXIS Inc

Bullboard Posts

Comment by dmacdon Feb 05, 2019 4:51pm

30 Views

Post# 29322898

RE:RE:RE:RE:RE:RE:RE:nice jump

I would prefer buy out if each marketing approval is sold one at a time. Otherwise we will get a fraction of the value in this market. Marketing could be easy since it fills a hospital need and the customers are those who distribute to hospital networks or the hospital itself. There will be a delay though for insurers to recognize the drug for reimbursement but the patient will have to pay if they have the cash if fluconazole fails. I have oversimplified but much easier than chasing doctors to issue prescriptions for the home market. Still expect a year from approvals to balance sheet as hospitals will ease in.

Bullboard Posts

Critical raw materials pioneer drives Europe’s clean energy transition